Abstract

To investigate the effect of sevoflurane combined with ulinastatin on cell proliferation and migration of human lung adenocarcinoma. Human lung adenocarcinoma cells H1975 were cultured in vitro, and treated with different concentrations of sevoflurane, ulinastatin and sevoflurane+ulinastatin, the cells were divided into control group, sevoflurane, ulinastatin and sevoflurane+ulinastatin group by cell counting kit 8; H1975 cell cycle by flow cytometry; the number of H1975 cells was measured by Transwell; protein immunoblot (Western blot). Compared with the control group, different concentrations of sevoflurane and ulinastatin treatment significantly inhibited the proliferation of H1975 cells in a dose-dependent manner. Sevoflurane combined with ulinastatin had a synergistic effect on cell proliferation inhibition in H1975 cells. Compared with the control group, the inhibition of cell proliferation and the proportion of cells in growth 0/growth 1 phase were significantly increased in the sevoflurane and ulinastatin groups, the proportion of cells in S phase, the number of cell migration, proliferation proteins cyclin D1, cyclin-dependent kinase 4, migration protein matrix metalloproteinase-2 and matrix metalloproteinase-9 were significantly decreased (p<0.05); compared with the sevoflurane group and the ulinastatin group, the inhibition of cell proliferation and the percentage of cells in growth 0/growth 1 group, the proportion of cells in S phase, cell migration number, proliferation proteins cyclin D1, cyclin-dependent kinase 4, migration proteins matrix metalloproteinase-2 and matrix metalloproteinase-9 were significantly decreased (p<0.05). Sevoflurane combined with ulinastatin can synergistically downregulate proliferation and migration protein expression and then inhibit the proliferation and migration of lung adenocarcinoma cells H1975, which may be a potential treatment for lung adenocarcinoma in clinical practice.